Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 845

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 5
Chunk 845
---
,423,237  
     842,500 
  
    Promissory Note - Others 
     1,350,292  
     975,000 
  
    Total current liabilities 
     7,547,084  
     5,603,980 

    Deferred underwriter compensation 
     2,887,500  
     2,887,500 
  
    Total liabilities 
     10,434,584  
     8,491,480 

    Commitments and contingencies 

    Class A ordinary shares subject to possible redemption 751,837 and 4,537,829 shares at redemption value of $12.00 and $11.12 per share as of December 31, 2024 and 2023, respectively 
     9,021,005  
     50,477,963 

    Shareholders’ Deficit: 

    Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding 
     -  
     - 
  
    Class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized, 510,000 shares issued and outstanding (excluding 751,837 and 4,537,829 shares subject to possible redemption as of December 31, 2024 and 2023, respectively subject to possible redemption) 
     51  
     51 
  
    Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized, 2,062,500 shares issued and outstanding 
     206  
     206 
  
    Accumulated deficit 
     (10,417,973) 
     (8,282,297)
  
    Total shareholders’ deficit 
     (10,417,716) 
     (8,282,040)
  
    Total Liabilities and Shareholders’ Deficit 
    $9,037,873  
    $50,687,403 

The
accompanying notes are an integral part of these consolidated financial statements.

F-4

DENALI CAPITAL ACQUISITION CORP.

CONSOLDATED STATEMENTS OF OPERATIONS

    For the  
    For the 

    Year Ended  
    Year Ended 

    December 31,  2024  
    December 31, 2023